153 related articles for article (PubMed ID: 29219612)
1. Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma.
Kaufman HL; Hunger M; Hennessy M; Schlichting M; Bharmal M
Future Oncol; 2018 Feb; 14(3):255-266. PubMed ID: 29219612
[TBL] [Abstract][Full Text] [Related]
2. Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial.
Lambert J; Marrel A; D'Angelo SP; Burgess MA; Chmielowski B; Fazio N; Gambichler T; Grob JJ; Lebbé C; Robert C; Russell J; Güzel G; Bharmal M
Patient; 2020 Aug; 13(4):457-467. PubMed ID: 32472503
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
D'Angelo SP; Russell J; Lebbé C; Chmielowski B; Gambichler T; Grob JJ; Kiecker F; Rabinowits G; Terheyden P; Zwiener I; Bajars M; Hennessy M; Kaufman HL
JAMA Oncol; 2018 Sep; 4(9):e180077. PubMed ID: 29566106
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.
Bharmal M; Nolte S; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Pusceddu S; Hanna GJ; Hassel JC; Kiecker F; Ellers-Lenz B; Bajars M; Güzel G; Nghiem P; Hunger M; Schlichting M; Henry-Szatkowski M; D'Angelo SP
Future Oncol; 2020 Sep; 16(27):2089-2099. PubMed ID: 32938212
[No Abstract] [Full Text] [Related]
5. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
[TBL] [Abstract][Full Text] [Related]
6. Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma.
Bharmal M; Fofana F; Barbosa CD; Williams P; Mahnke L; Marrel A; Schlichting M
Health Qual Life Outcomes; 2017 Dec; 15(1):247. PubMed ID: 29273043
[TBL] [Abstract][Full Text] [Related]
7. Avelumab and other recent advances in Merkel cell carcinoma.
Bommareddy PK; Kaufman HL
Future Oncol; 2017 Dec; 13(30):2771-2783. PubMed ID: 28976209
[TBL] [Abstract][Full Text] [Related]
8. Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma.
Bharmal M; Nolte S; Henry-Szatkowski M; Hennessy M; Schlichting M
Health Qual Life Outcomes; 2020 May; 18(1):145. PubMed ID: 32430019
[TBL] [Abstract][Full Text] [Related]
9. In brief: Avelumab (Bavencio) for metastatic merkel cell carcinoma.
Med Lett Drugs Ther; 2017 Jul; 59(1521):e120. PubMed ID: 28699934
[No Abstract] [Full Text] [Related]
10. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
Kaufman HL; Russell JS; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Milella M; Brownell I; Lewis KD; Lorch JH; von Heydebreck A; Hennessy M; Nghiem P
J Immunother Cancer; 2018 Jan; 6(1):7. PubMed ID: 29347993
[TBL] [Abstract][Full Text] [Related]
11. Avelumab: A Review of Its Application in Metastatic Merkel Cell Carcinoma.
Joseph J; Zobniw C; Davis J; Anderson J; Trinh VA
Ann Pharmacother; 2018 Sep; 52(9):928-935. PubMed ID: 29616562
[TBL] [Abstract][Full Text] [Related]
12. Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.
D'Angelo SP; Hunger M; Brohl AS; Nghiem P; Bhatia S; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Schlichting M; Hennessy MH; Bharmal M
Cancer Immunol Immunother; 2019 Apr; 68(4):609-618. PubMed ID: 30721341
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of avelumab versus chemotherapy in Merkel cell carcinoma: innovative use of patient insights.
Bharmal M; Marrel A; Hennessy M; Fofana F; Lambert J; Arnould B
J Comp Eff Res; 2018 Sep; 7(9):881-890. PubMed ID: 30107762
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
Gaiser MR; Bongiorno M; Brownell I
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):345-359. PubMed ID: 29478343
[TBL] [Abstract][Full Text] [Related]
15. Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell Carcinoma.
Bharmal M; Hunger M; Schlichting M
Value Health; 2019 Oct; 22(10):1170-1177. PubMed ID: 31563260
[TBL] [Abstract][Full Text] [Related]
16. Avelumab: a new standard for treating metastatic Merkel cell carcinoma.
Baker M; Cordes L; Brownell I
Expert Rev Anticancer Ther; 2018 Apr; 18(4):319-326. PubMed ID: 29482384
[TBL] [Abstract][Full Text] [Related]
17. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.
Kelly K; Infante JR; Taylor MH; Patel MR; Wong DJ; Iannotti N; Mehnert JM; Loos AH; Koch H; Speit I; Gulley JL
Cancer; 2018 May; 124(9):2010-2017. PubMed ID: 29469949
[TBL] [Abstract][Full Text] [Related]
18. Avelumab: A Review in Metastatic Merkel Cell Carcinoma.
Shirley M
Target Oncol; 2018 Jun; 13(3):409-416. PubMed ID: 29799096
[TBL] [Abstract][Full Text] [Related]
19. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.
Cowey CL; Liu FX; Kim R; Boyd M; Fulcher N; Krulewicz S; Kasturi V; Bhanegaonkar A
Future Oncol; 2021 Jun; 17(18):2339-2350. PubMed ID: 33709776
[TBL] [Abstract][Full Text] [Related]
20. Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East.
Ascierto PA; Orlova K; Grignani G; Dudzisz-Śledź M; Fenig E; Chiarion Sileni V; Fazio N; Samimi M; Mortier L; Gebhardt C; Kramkimel N; Steven N; Bechter O; Arance A; Benincasa E; Kostkova L; Costa N; Lorigan P
Int J Cancer; 2021 Dec; 149(11):1926-1934. PubMed ID: 34310716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
